Radioligand Therapy (RLT) Market Research Report Information by Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, and Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, and Others), By End User (Hospitals & Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

Global Radioligand Therapy (RLT) Market Overview

Radioligand Therapy (RLT) Market Size was valued at USD 6.80 billion in 2022. The Radioligand Therapy (RLT) Market industry is projected to grow from USD 7.44 billion in 2023 to USD 13.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.41% during the forecast period (2023 - 2030).

The factors positively contributing to the market growth are increasing incidences of cancer and growing number of product launches and pipeline products.  

Radioligand Therapy (RLT) Market Trends

• Increasing incidences of cancer

Radioligand is the fastest-growing therapy commonly utilize for diagnosing and treating various types of cancers such as prostate cancer and breast cancer. Manufacturers are bringing innovation into the pipeline to target a larger range of cancers. As per the World Cancer Research Fund International, prostate cancer accounted for the second-highest ranking globally in 2020 with more than 1.4 million new cases. Cancer remains a global health concern, and the rising incidence of various types of cancer is driving the demand for effective treatment options. Radioligand therapy offers a promising approach for targeted cancer treatment, particularly in cases where traditional therapies have limited efficacy.

Moreover, the growing number of product launches and pipeline products drives market growth. For instance, in March 2021, Novartis AG (Switzerland) enhanced its targeted radioligand therapy pipeline by obtaining an in-license to commercialize fibroblast activation protein (FAP), which includes FAPI-46 and FAPI-74, through SOFIE Biosciences, Inc. (US). Hence, the increasing prevalence of cancer and the high focus on bringing pipeline products into the market is driving the growth of the market.

Furthermore, nuclear medicine techniques, including radioligand therapy, have witnessed significant technological advancements in recent years. The development of novel radiopharmaceuticals and improved imaging and therapeutic modalities have expanded the potential applications of radioligand therapy, driving market growth.

Radioligand Therapy (RLT) Segment Insights

Radioligand Therapy (RLT) Isotope Insights

The Radioligand Therapy (RLT) Market is segmented, based on isotope, into fluorine – 18, gallium – 68, lutetium – 177, and others including actinium-225 and iodine-131. The fluorine – 18 segment held the majority share of the market, with a market share of approximately 40-55% in 2022, and lutetium – 177 is the fastest-growing segment during the forecast year. Fluorine – 18 is the most commonly utilize isotope and is mostly utilized in Positron Emission Tomography (PET) to target the cyclooxygenase-2 (COX-2) isozyme for the diagnosis of cancer including ovarian, prostate, breast, and cervical cancer.

Radioligand Therapy (RLT) Targeted Receptor Insights

The Radioligand Therapy (RLT) Market segmentation, based on targeted receptor, includes the prostate-specific membrane antigen (PSMA), somatostatin receptor (SSTR), epidermal growth factor receptor (EGFR), and others including gastrin-releasing peptide receptor (GRPR) and human epidermal growth factor receptor 2 (HER2). The PSMA segment dominated the market in the base year, i.e., 2022, and is the fastest-growing segment during the forecast period, 2023–2030. This is due to the increasing prevalence of prostate cancer and an increasing number of product launches & pipeline products. For instance, according to GLOBOCAN 2020, prostate cancer accounted for 7.3% of all cases globally in both sexes.   Moreover, in March 2022, Novartis AG received US Food and Drug Administration approval for the product, namely Pluvicto, which is utilized in the treatment of PSMA-positive metastatic castration-resistant prostate cancer.

FIGURE 2: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2022 & 2030 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Radioligand Therapy (RLT) Indication Insights

The Radioligand Therapy (RLT) Market segmentation, based on indication, includes prostate cancer, neuroendocrine tumors (NETS), breast cancer, and others including lymphoma and non-Hodgkin’s, lymphoma, lung cancer, pancreatic cancer, and atherosclerosis. The prostate cancer segment held the largest market share in 2022, and NETS is the fastest-growing segment during the forecast period. Moreover, one of the most renowned products, namely Lutathera, manufactured by Novartis AG (Switzerland), is primarily utilized for the treatment of NETS by alleviating the alkaline phosphatase (ALP) liver enzyme.

Radioligand Therapy (RLT) End User Insights

Based on end user, the Radioligand Therapy (RLT) Market has been segmented into hospitals & clinics, diagnostic centers, and others including ambulatory surgical centers and research & academic institutes. The hospitals & clinics segment dominated the market in the base year, i.e., 2022, and diagnostic centers is the fastest-growing segment during the forecast period, 2023–2030. Furthermore, the factors influencing the growth of the end-user segment are rising incidences of cancer across the globe and higher adoption of a sedentary lifestyle, which may increase the chances of having various types of cancer.

Radioligand Therapy (RLT) Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and the rest of the world. In North America, the radioligand therapy market held the largest market share in 2022 due to the presence of major players in the US such as Lantheus Holdings, Inc. (US) and POINT Biopharma Global Inc. (US) and the huge number of clinical trials ongoing based on radioligand therapy. In addition, the rising incidences of cancer across the region also boost the market growth. In September 2022, the Centres for Disease Control and Prevention announced that 264,000 women and 2,400 men are diagnosed with breast cancer in the US each year.

Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

FIGURE 3: RADIOLIGAND THERAPY (RLT) MARKET, BY REGION, 2022 & 2030 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe radioligand therapy (RLT) market accounted for the second-largest market share due to the growing facilities and infrastructure in the hospitals & clinics for the adoption of radioligand therapies and Europe’s major countries' population contributions to the clinical trials of the radioligand. For instance, in January 2023, Novartis AG (Switzerland) chose Spain for the development of the radioligand Pluvicto, which has been approved by the European Commission. Furthermore, the Germany radioligand therapy (RLT) market held the largest market in 2022, and the UK radioligand therapy (RLT) market is projected to be the fastest-growing market in the Europe region.

The Asia-Pacific radioligand therapy (RLT) market is the fastest growing region from 2023 to 2030, owing to the growing incidence of cancer and the rising geriatric population in the region. Furthermore, the Union for International Cancer Control (UICC) found through research that people over 65 are 11 times more likely to develop cancer compared to younger people, which drives the growth of the region’s market because of the large number of geriatrics. Moreover, the Japan radioligand therapy (RLT) market accounted for the largest market share in 2022, and the China radioligand therapy (RLT) market is projected to be the fastest-growing market in the Asia-Pacific region.

Radioligand Therapy (RLT) Key Market Players & Competitive Insights

Major market players are investing heavily in R&D in order to expand their product lines, which will help the radioligand therapy (RLT) market grow even further. Market participants are also expanding their global footprint through a variety of strategic initiatives such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations.

Novartis AG (Switzerland) was established through a merger of Ciba-Geigy and Sandoz. Novartis AG and its preceding companies have developed innovative products for over 250 years. It has a strong presence in North America, Europe, Asia-Pacific, and the Middle East & Africa. Furthermore, in March 2022, the company received approval for Novartis Pluvicto from the US Food and Drug Administration. This radioligand therapy is utilized in the treatment of PSMA-positive metastatic castration-resistant prostate cancer. Furthermore, this launch is fulfilling customer demand as it is based on precision medicine and is assisting in generating revenue for the company's cancer product portfolio.

Key Companies in the Radioligand Therapy (RLT) Market Includes

• Novartis AG (Switzerland)


• POINT Biopharma Global Inc. (US)


• Molecular Partners (Switzerland)


• Telix Pharmaceuticals Limited (Australia)


• Fusion Pharma (US)


• Lantheus Holdings, Inc. (US)


• Curium (France)


• Precrix (Belgium)


• Orano Group (Paris)


• Artios Pharma (UK)

Radioligand Therapy (RLT) Industry Developments

• March 2023: Telix Pharmaceuticals Limited (Australia) received approval for Illuccix (a kit for the preparation of gallium Ga 68 gozetotide injection), which is utilized to treat metastatic prostate cancer. The expanded indication of Illuccix will create a lucrative growth opportunity for the company.


• November 2022: Lantheus Holdings, Inc. (US) and POINT Biopharma Global Inc. (US) both entered into a collaboration for the commercialization of PNT2002 & PNT2003. This collaborated agreement broadens Lantheus Holdings Inc.’s prostate cancer franchise.

Radioligand Therapy (RLT) Market Segmentation

Radioligand Therapy (RLT) Isotope Outlook

• Fluorine - 18


• Gallium - 68


• Lutetium - 177


• Others

Radioligand Therapy (RLT) Targeted Receptor Outlook

• Prostate-specific Membrane Antigen (PSMA)


• Somatostatin Receptor (SSTR)


• Epidermal Growth Factor Receptor (EGFR)


• Others

Radioligand Therapy (RLT) Indication Outlook

• Prostate Cancer


• Neuroendocrine Tumors (NETs)


• Breast Cancer


• Others

Radioligand Therapy (RLT) End User Outlook

• Hospitals & Clinics


• Diagnostic Centers


• Others

Radioligand Therapy (RLT) Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America